YS Biopharma Announces Financial Results for Fiscal Year 2023 Ended March 31, 2023

Total revenues increase by 36.3% year-over-year; gross margin improves to 77.7%; balance sheet remains robust
Company's PIKA rabies vaccine approved for Phase III clinical trials in Singapore, the...

Related Keywords

Philippines ,Hong Kong ,Canada ,China ,Singapore ,Pakistan ,United States ,Robin Yang ,David Shao ,Alyssa Li ,Prnewswire Ys Biopharma Co Ltd ,Exchange Rate Information ,Nasdaq ,Development Expenses ,Source Ys Biopharma Co Ltd ,Summit Healthcare Acquisition Corp ,Rsys Group ,Securities Exchange ,Fiscal Year ,Summit Healthcare Acquisition ,Nasdaq Capital Market ,States Toll Free ,China Toll Free ,Toll Free ,Federal Reserve Board ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Business Combination ,Ended March ,